Therapeutic Advances in Medical Oncology (Mar 2022)

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

  • Isabel Heidegger,
  • Claudia Kesch,
  • Alexander Kretschmer,
  • Igor Tsaur,
  • Francesco Ceci,
  • Massimo Valerio,
  • Derya Tilki,
  • Giancarlo Marra,
  • Felix Preisser,
  • Christian D. Fankhauser,
  • Fabio Zattoni,
  • Peter Chiu,
  • Ignacio Puche-Sanz,
  • Jonathan Olivier,
  • Roderik C. N. van den Bergh,
  • Veeru Kasivisvanathan,
  • Andreas Pircher,
  • Irene Virgolini,
  • Giorgio Gandaglia

DOI
https://doi.org/10.1177/17588359221081922
Journal volume & issue
Vol. 14

Abstract

Read online

Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.